In short
Parkinson's research continued alongside work on dosing strategy. Zhittya presented its research at FreedomFest 2025.
Most of the June 2025 update covered other research areas and company business. The parts about the brain research are summarized here.
Dosing for brain conditions
Dan Montano, the chief executive, wrote that Zhittya was continuing its work in Parkinson's disease, stroke, dementia and other brain conditions, and that the team still did not know the best dosing schedule for them. Dosing had gone from level 1 to level 23. The length of dosing had gone from a single round to three years. The team had tried five different devices for delivering FGF-1 through the nose, and Vika Montano was testing a sixth, with Mr. Montano as the first to try it.
He wrote that the brain's complexity made this a slow and deliberate process, and that doses had to be raised slowly and carefully so as to first do no harm. The work was budgeted for the coming year. Because the right dosing was better understood in several other research areas, he said those would become the company's near-term priority.
Participant reports
The update shared comments from participants and family members. The first imaging participant had his one-year follow-up scan at Washington University in St. Louis around the start of June. His family wrote about facial expression, alertness and memory. The update did not give results from that scan.
Other comments covered walking, balance, driving, tremor, sense of smell, handwriting and golf. One participant gave a mixed report, describing some things as better and others, including freezing while walking, tremor and fatigue, as unchanged or worse. The update also pointed to a long account written by a physician who had taken part.
Dr. Jacobs on monitoring and delivery
Dr. Jack Jacobs, the company's president, wrote that participants with Parkinson's were followed closely, including with a set of laboratory tests to make sure FGF-1 was not altering their blood chemistry.
He also described a study in rats, done with a group of scientists in Minnesota, that compared how much FGF-1 reaches the brain when given through the nose and when given into a vein. Almost twice as much reached most brain regions by the nasal route.
This summary covers the Parkinson's research in the June 2025 update. The complete update, including the other topics it covered, is below.
Read the complete June 2025 update as published
The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.